GMED vs BIO
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 08, 2026
GMED
52.8
AI Score
VS
BIO Wins
BIO
60.1
AI Score
Investment Advisor Scores
BIO
60score
Recommendation
BUY
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | GMED | BIO | Winner |
|---|---|---|---|
| Revenue | 759.85M | 592.10M | GMED |
| Net Income | 124.30M | -527.10M | GMED |
| Net Margin | 16.4% | -89.0% | GMED |
| Operating Income | 150.39M | 34.10M | GMED |
| ROE | 2.6% | -7.7% | GMED |
| ROA | 2.3% | -5.4% | GMED |
| Total Assets | 5.44B | 9.79B | BIO |
| Cash | 560.95M | 507.20M | GMED |
| Current Ratio | 4.56 | 3.21 | GMED |
| Free Cash Flow | 162.75M | 78.10M | GMED |
Frequently Asked Questions
Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.